<DOC>
	<DOC>NCT00115154</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.</brief_summary>
	<brief_title>Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>18 years of age Have AK on arm or hand Discontinuation of sun tanning and the use of tanning beds Discontinuation of the use of moisturizers, body oils, overthecounter retinol products and products containing alpha or beta hydroxy acid in the treatment and surrounding area Withholding of the use of sunscreen in the treatment area for 24 hours prior to all study visits and for 8 hours before applying study cream Postponement of the treatment of nonstudy AK lesions anywhere on the arm being treated until study participation is complete Subjects must not have any evidence of systemic cancer or immunosuppression or other unstable health conditions Participation in another clinical study Have previously received treatment with imiquimod within the treatment area Have squamous cell carcinoma (SCC), basal cell carcinoma (BCC), or other malignancy in the treatment or surrounding area that requires treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>3M Pharmaceuticals</keyword>
	<keyword>Aldara</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>Actinic Keratosis (AK)</keyword>
</DOC>